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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
We aim to look at the benefits and harms of the use of urinary alkalisers for the treatment of uncomplicated UTIs in adult women.
B A C K G R O U N D
Description of the condition
Urinary tract infection (UTI) is the most common form of
bacterial infection in women, most of which are uncompli-
cated (Foxman 2003). UTIs are considered uncomplicated in
the absence of urinary tract abnormalities, obstruction or resis-
tant pathogens, pregnancy, immunocompromised state, or acute
pyelonephritis. The term ’uncomplicated’ is not applied to UTIs
in adult men.
Standard conventional management of suspected UTI is to con-
firm presence of either bacteria or white cells in the urine, and
treat with antibiotics. However, studies have challenged this ap-
proach. Whatever the role of antibiotics, women often seek relief
from the symptoms of UTI until either the infection is cleared
with antibiotics or resolves spontaneously. Uncomplicated UTI
often spontaneously remit without antibiotics: a recent pilot ran-
domised controlled trial (RCT) found that symptomatic treat-
ment for uncomplicated UTI was non-inferior to antimicrobial
therapy (Bleidorn 2010). Nonetheless, an earlier study also found
that women with culture-negative symptoms of UTI respond to
antibiotics (Richards 2005).
Description of the intervention
Several clinical guidelines for UTI treatment advise first-line use
of antibiotics (ACOG 2008; Grabe 2010; IDSA/ESMI 2011).
However, until infection has cleared (due to either antimicrobial
therapy or spontaneous remit), symptoms may be troublesome.
The use of urinary alkalisers for the symptomatic treatment of
uncomplicated UTI is very common in some countries. For ex-
ample, more than one million units of urinary alkalisers are sold
in Australia annually; many of these are used specifically for UTIs
and acute culture-negative cystitis. Use of urinary alkalisers for the
symptomatic treatment of UTI and cystitis appear in MIMS Aus-
tralia and other national formularies (eMC 2013; MIMS 2013).
Use is also widely promoted by primary healthcare practitioners.
Literature supporting benefits from use of these agents is sparse;
some guidelines specifically state that they are not recommended
(NICE 2009).
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How the intervention might work
Urinary alkalisers primarily work to raise urine pH, which in the-
ory, aids in the symptomatic treatment of dysuria. Dysuria and
urinary frequency are the most common and bothersome symp-
toms of UTI and acute culture-negative cystitis (Munday 1990;
Spooner 1984).
Urinary pathogens, such as Proteus mirabilis can also increase uri-
nary pH and are associated with symptoms of dysuria and uri-
nary frequency (Franz 1999); however, it has been suggested else-
where that raising urine pHdoes not affect the sensation of dysuria
(Brumfitt 1990).
Why it is important to do this review
Uncomplicated UTI is very common, and imposes significant fi-
nancial burden. In the US, UTI is responsible for over seven mil-
lion physician visits annually, and account for the use of approx-
imately 15% of all community-prescribed antibiotics. The total
annual estimated cost of antibiotics for UTI in the USA exceeds
one billion USD (Foxman 2002; Mazzulli 2002). The advent of
increasing numbers of drug resistant organisms means that avoid-
ance of unnecessary antibiotics is important.
Urinary alkalisers are widely used globally for symptomatic relief of
UTI and acute culture-negative cystitis. There is however a paucity
of good evidence to support their use. There is also conflicting ev-
idence surrounding urinary alkalinisation for antimicrobial eradi-
cation in UTI. Some studies show benefit of concomitant urinary
alkalisers and antibiotic use, with reduced antibiotic MIC when
urine is at alkaline pH. Other studies show that urine pH within
the acidic range is favourable, as it can have a bactericidal effect
(Burian 2012; Carlsson 2003; Zhanel 1991). Although we aim to
focus on symptom relief in UTI, antimicrobial eradication may
also be important, as prolonged positive urine culture may lead
to a prolongation of symptoms. If we find insufficient evidence
surrounding these agents, then this sets a research agenda.
O B J E C T I V E S
We aim to look at the benefits and harms of the use of urinary al-
kalisers for the treatment of uncomplicated UTIs in adult women.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All RCTs and quasi-RCTs (RCTs in which allocation to treatment
was obtained by alternation, use of alternate medical records, date
of birth or other predictable methods) looking at the use of urinary
alkalisers (of any type) for the symptomatic relief of UTI.
Types of participants
Inclusion criteria
We will include women aged 16 years or over with symptoms of
uncomplicated UTI or cystitis including urinary frequency and
dysuria. Participants will be included regardless of whether diag-
noses were made from positive urine dipstick test results or pos-
itive urine culture. Women with recurrent UTI may be included
if they were not symptomatic in the previous two weeks.
Exclusion criteria
• Complicated UTIs, such as those requiring hospital
admission, infections associated with fevers or rigours, multidrug
resistant pathogens Neisseria gonorrhoeae and Chlamydia
trachomatis urethritis, urinary tract abnormalities, urinary tract
calculi or urinary tract obstruction
• Immunocompromising conditions
• Acute pyelonephritis
• UTI symptoms in the previous two weeks
• Chronic conditions such as interstitial cystitis, painful
bladder syndrome, chronic pelvic pain syndrome.
Types of interventions
Any urinary alkaliser used exclusively or non-exclusively for the
treatment of symptoms of UTI will be included. We plan to com-
pare:
• Urinary alkalisers versus placebo/no treatment
• Urinary alkalisers versus antibiotics
• Urinary alkalisers + antibiotics versus antibiotics alone
• Urinary alkalisers versus anti-inflammatories.
Types of outcome measures
Primary outcomes
• Early and late symptoms (at days 1 to 4 and days 5 to 10):
dysuria, urinary frequency, and abdominal pain
• Any adverse events: worsening of UTI, progression to
complicated UTI, need for hospitalisation or intravenous
antibiotics.
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Secondary outcomes
• Duration of symptoms
• Severity of symptoms (negligible, mild, moderate, severe) as
measured on days 1 to 4 and days 5 to 10
• Number of return visits to the GP
• Days absent from work
• Bacterial eradication.
Search methods for identification of studies
Electronic searches
We will search the Cochrane Renal Group’s Specialised Register
through contact with the Trials’ Search Co-ordinator using search
terms relevant to this review. The Cochrane Renal Group’s Spe-
cialised Register contains studies identified from the following
sources.
1. Monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL)
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the
proceedings of major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register
(ICTRP) Search Portal and ClinicalTrials.gov.
Studies contained in the SpecialisedRegister are identified through
search strategies for CENTRAL,MEDLINE, andEMBASE based
on the scope of the Cochrane Renal Group. Details of these strate-
gies, as well as a list of handsearched journals, conference proceed-
ings and current awareness alerts, are available in the Specialised
Register section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of clinical practice guidelines, review articles
and relevant studies.
2. Letters seeking information about unpublished or
incomplete studies to investigators known to be involved in
previous studies.
Data collection and analysis
Selection of studies
The search strategy described will be used to obtain titles and
abstracts of studies that may be relevant to the review. The titles
and abstracts will be screened independently by two authors, who
will discard studies that are not applicable; however studies and
reviews that might include relevant data or information on studies
will be retained initially. Two authors will independently assess
retrieved abstracts and, if necessary the full text, of these studies
to determine which studies satisfy the inclusion criteria.
Data extraction and management
Data extraction will be carried out independently by two authors
using standard data extraction forms. Studies reported in non-
English language journals will be translated before assessment.
Where more than one publication of one study exists, reports will
be grouped together and the publication with the most complete
data will be used in the analyses. Where relevant outcomes are
only published in earlier versions these data will be used. Any
discrepancy between published versions will be highlighted.
Assessment of risk of bias in included studies
The following items will be independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?
◦ Participants and personnel
◦ Outcome assessors
• Were incomplete outcome data adequately addressed
(attrition bias)?
• Are reports of the study free of suggestion of selective
outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could
put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes such as resolution of symptoms by
day three and day seven (dysuria, urinary frequency, abdominal
pain) andprogression to complicatedUTI, resultswill be expressed
as risk ratio (RR) with 95% confidence intervals (CI). Where
continuous scales of measurement are used to assess the effects of
treatment, such as duration of symptoms, severity of symptoms
(negligible, mild, moderate, severe; 0 to 3), the mean difference
(MD) will be used, or the standardised mean difference (SMD) if
different scales have been used.
Unit of analysis issues
In relation to cluster-RCTs, only studies where analyses were made
at the same level as allocation (and using summary measurements
for each cluster) will be included. Cluster-RCTs may also be in-
cluded if statistical methods were employed to deal with analysis
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at the individual level, which can account for the clustering of the
data, and that these statistical methods were clearly outlined in the
methods, and are sound.
Data from cross-over RCTs may be assessed, but only the first
randomisation period will be included. Complete cross-over data
are not appropriate for the intervention under review.
Urinary alkalisers could be investigated alone or in combination
with another agent(s) where the only difference between groups
was addition of a urinary alkaliser. Where possible we aim to com-
bine groups with the same intervention and create a single pair-
wise comparison.
Dealing with missing data
Any further information required from original authors will be
requested by written correspondence (e.g. emailing or writing to
corresponding author) and any relevant information obtained in
thismannerwill be included in the review. Evaluationof important
numerical data such as screened, randomised patients as well as
intention-to-treat, as-treated and per-protocol population will be
carefully performed. Attrition rates, for example drop-outs, losses
to follow-up and withdrawals will be investigated. Issues of miss-
ing data and imputation methods (e.g. last-observation-carried-
forward) will be critically appraised (Higgins 2011).
Assessment of heterogeneity
Heterogeneity will be analysed using a Chi² test on N-1 degrees
of freedom, with an alpha of 0.05 used for statistical significance
and with the I² test (Higgins 2003). I² values of 25%, 50% and
75% correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
If possible, funnel plots will be used to assess for the potential
existence of small study bias (Higgins 2011).
Data synthesis
Data will be pooled using the random-effects model but the fixed-
effect model will also be used to ensure robustness of the model
chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis will be used to explore possible sources of
heterogeneity (e.g. participants, interventions and study quality).
Heterogeneity among participants could be related to age, uri-
nary pathogen (including urinary bacterial cell counts), chronicity
of symptoms before seeking medical advice, and history of uri-
nary symptoms (including recurrent UTIs). If data are available
we will perform a subgroup analysis comparing the use of urinary
alkalisers in sporadic and recurrent UTIs. Heterogeneity in treat-
ments could be related to prior or concomitant (or both) agent(s)
used and the agent, dose and duration of therapy. These could in-
clude antibiotics, analgesics and anti-inflammatory medications.
We plan to perform a subgroup analysis comparing doses and du-
ration of urinary alkaliser therapy. Adverse effects will be tabulated
and assessed using descriptive techniques, because they are likely
to be different for the various agents used. Where possible, the risk
difference with 95% CI will be calculated for each adverse effect,
either compared with no treatment or another agent.
Sensitivity analysis
We will perform sensitivity analyses in order to explore the influ-
ence of the following factors on effect size.
• Repeating the analysis excluding unpublished studies
• Repeating the analysis taking account of risk of bias, as
specified
• Repeating the analysis excluding any very long or large
studies to establish how much they dominate the results
• Repeating the analysis excluding studies using the following
filters: diagnostic criteria, language of publication, source of
funding (industry versus other), and country.
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A P P E N D I C E S
Appendix 1. Electronic search strategies
Database Search terms
CENTRAL 1. urinary next tract next infection*:ti,ab,kw
2. bacteriuri*:ti,ab,kw
3. cystitis:ti,ab,kw
4. pyelonephritis:ti,ab,kw
5. (uti or utis):ti,ab,kw
6. {or #1-#5}
7. dysuria:ti,ab,kw
8. stranguria:ti,ab,kw
9. ((pain* or frequen* or urgency) near/25 (micturation or urin*)):ti,ab,kw
10. {or #7-#9}
11. #6 or #10
12. sodium next bicarbonate:ti,ab,kw
13. citrate*:ti,ab,kw
14. “citric acid”:ti,ab,kw
15. alkali*:ti,ab,kw
16. {or #12-#15}
17. #11 and #16
MEDLINE 1. urinary tract infections/
2. bacteriuria/
3. cystitis/
4. Pyelonephritis/
5. urinary tract infection*.tw.
6. (uti or utis).tw.
7. bacteriuri*.tw.
8. cystitis.tw.
9. pyelonephritis.tw.
10. or/1-9
11. Dysuria/
12. stranguria.tw.
13. dysuria.tw.
14. ((pain* or frequen* or urgency) adj25 (micturation or urin*)).tw.
15. or/11-14
16. or/10,15
17. Sodium Bicarbonate/
18. exp Citrates/
19. sodium bicarbonate.tw,nm.
20. citrate.tw,nm.
21. alkali*.tw.
22. or/17-21
23. and/16,22
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(Continued)
EMBASE 1. Urinary Tract Infection/
2. Bacteriuria/
3. Asymptomatic Bacteriuria/
4. Cystitis/
5. exp Pyelonephritis/
6. urinary tract infection*.tw.
7. (uti or utis).tw.
8. bacteriuri*.tw.
9. cystitis.tw.
10. pyelonephritis.tw.
11. or/1-10
12. Dysuria/
13. Urinary Urgency/
14. Urinary Frequency/
15. stranguria.tw.
16. dysuria.tw.
17. ((pain* or frequen* or urgency) adj25 (micturation or urin*)).tw.
18. or/12-17
19. or/11,18
20. Alkalinization/
21. Bicarbonate/
22. Citric Acid/
23. Citrate Sodium/
24. Citrate Potassium Sodium/
25. Citrate Potassium/
26. sodium bicarbonate.tw.
27. citrate*.tw,rn.
28. alkali*.tw.
29. or/20-28
30. and/19,29
Appendix 2. Risk of bias assessment tool
Potential source of bias Assessment criteria
Random sequence generation
Selection bias (biased allocation to interventions) due to inade-
quate generation of a randomised sequence
Low risk of bias: Random number table; computer random num-
ber generator; coin tossing; shuffling cards or envelopes; throwing
dice; drawing of lots; minimization (minimization may be imple-
mented without a random element, and this is considered to be
equivalent to being random)
High risk of bias: Sequence generated by odd or even date of birth;
date (or day) of admission; sequence generated by hospital or
clinic record number; allocation by judgement of the clinician; by
preference of the participant; based on the results of a laboratory
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(Continued)
test or a series of tests; by availability of the intervention
Unclear: Insufficient information about the sequence generation
process to permit judgement
Allocation concealment
Selection bias (biased allocation to interventions) due to inade-
quate concealment of allocations prior to assignment
Low risk of bias: Randomisation method described that would not
allow investigator/participant to know or influence intervention
group before eligible participant entered in the study (e.g. central
allocation, including telephone, web-based, and pharmacy-con-
trolled, randomisation; sequentially numbered drug containers of
identical appearance; sequentially numbered, opaque, sealed en-
velopes)
High risk of bias:Using an open random allocation schedule (e.g. a
list of random numbers); assignment envelopes were used without
appropriate safeguards (e.g. if envelopes were unsealed or non-
opaque or not sequentially numbered); alternation or rotation;
date of birth; case record number; any other explicitly unconcealed
procedure
Unclear: Randomisation stated but no information on method
used is available
Blinding of participants and personnel
Performance bias due to knowledge of the allocated interventions
by participants and personnel during the study
Low risk of bias: No blinding or incomplete blinding, but the re-
view authors judge that the outcome is not likely to be influenced
by lack of blinding; blinding of participants and key study per-
sonnel ensured, and unlikely that the blinding could have been
broken
High risk of bias: No blinding or incomplete blinding, and the
outcome is likely to be influenced by lack of blinding; blinding
of key study participants and personnel attempted, but likely that
the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
Blinding of outcome assessment
Detection bias due to knowledge of the allocated interventions by
outcome assessors
Low risk of bias:Noblinding of outcome assessment, but the review
authors judge that the outcome measurement is not likely to be
influenced by lack of blinding; blinding of outcome assessment
ensured, and unlikely that the blinding could have been broken
High risk of bias: No blinding of outcome assessment, and the
outcome measurement is likely to be influenced by lack of blind-
ing; blinding of outcome assessment, but likely that the blinding
could have been broken, and the outcome measurement is likely
to be influenced by lack of blinding
Unclear: Insufficient information to permit judgement
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(Continued)
Incomplete outcome data
Attrition bias due to amount, nature or handling of incomplete
outcome data
Low risk of bias: No missing outcome data; reasons for missing
outcome data unlikely to be related to true outcome (for survival
data, censoring unlikely to be introducing bias); missing outcome
data balanced in numbers across intervention groups, with similar
reasons for missing data across groups; for dichotomous outcome
data, the proportion ofmissing outcomes comparedwith observed
event risk not enough to have a clinically relevant impact on the
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes not enough to have a clinically
relevant impact on observed effect size; missing data have been
imputed using appropriate methods
High risk of bias: Reason for missing outcome data likely to be
related to true outcome, with either imbalance in numbers or rea-
sons for missing data across intervention groups; for dichotomous
outcome data, the proportion ofmissing outcomes comparedwith
observed event risk enough to induce clinically relevant bias in
intervention effect estimate; for continuous outcome data, plau-
sible effect size (difference in means or standardized difference in
means) among missing outcomes enough to induce clinically rel-
evant bias in observed effect size; ‘as-treated’ analysis done with
substantial departure of the intervention received from that as-
signed at randomisation; potentially inappropriate application of
simple imputation
Unclear: Insufficient information to permit judgement
Selective reporting
Reporting bias due to selective outcome reporting
Low risk of bias: The study protocol is available and all of the
study’s pre-specified (primary and secondary) outcomes that are of
interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published
reports include all expected outcomes, including those that were
pre-specified (convincing text of this nature may be uncommon)
High risk of bias: Not all of the study’s pre-specified primary out-
comes have been reported; one or more primary outcomes is re-
ported using measurements, analysis methods or subsets of the
data (e.g. subscales) that were not pre-specified; one or more re-
ported primary outcomes were not pre-specified (unless clear jus-
tification for their reporting is provided, such as an unexpected
adverse effect); one or more outcomes of interest in the review are
reported incompletely so that they cannot be entered in a meta-
analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study
Unclear: Insufficient information to permit judgement
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(Continued)
Other bias
Bias due to problems not covered elsewhere in the table
Low risk of bias: The study appears to be free of other sources of
bias.
High risk of bias: Had a potential source of bias related to the spe-
cific study design used; stopped early due to some data-dependent
process (including a formal-stopping rule); had extreme baseline
imbalance; has been claimed to have been fraudulent; had some
other problem
Unclear: Insufficient information to assess whether an important
risk of bias exists; insufficient rationale or evidence that an iden-
tified problem will introduce bias
C O N T R I B U T I O N S O F A U T H O R S
1. Draft the protocol: DOK, SD, NG, FP, CDM
2. Study selection: DOK, SD, NG, FP, CDM
3. Extract data from studies: DOK, CMD, TH
4. Enter data into RevMan: DOK
5. Carry out the analysis: DOK, CDM, TH, SD, NG, FP
6. Interpret the analysis: DOK, CDM, TH, SD, NG, FP
7. Draft the final review: DOK
8. Disagreement resolution: DOK, CDM, TH
9. Update the review: DOK, CDM, TH, SD, NG, FP
D E C L A R A T I O N S O F I N T E R E S T
None known.
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